CHEMCONNECTION BV

Their core work

CHEMCONNECTION BV is a Dutch specialty chemistry SME based in Oss — a city with deep pharmaceutical industry roots, historically tied to major pharma manufacturing. Their clearest area of expertise is chiral chemistry: the CORE project places them at the frontier of continuous crystallization and deracemization, which are key industrial processes for producing enantiopure pharmaceutical compounds. They also contributed as an industry partner to the NANOMED training network, suggesting applied chemistry capabilities at the intersection of drug delivery and nanomaterial science. Their role in both projects was as an industry host and practitioner, not as a research institution — they bring real-world process chemistry knowledge into academic-industry consortia.

What they specialise in

How they've shifted over time

Both projects started in 2016, making it impossible to trace a meaningful evolution of focus from available data — there is no early versus late period to compare. No keywords were extracted from either project record, which further limits any trend analysis. What can be said is that CHEMCONNECTION entered H2020 with two simultaneous but distinct chemistry threads: fine-resolution chiral synthesis and nanomedicine applications, suggesting a company with broader pharmaceutical chemistry reach than a single-niche firm.

With both projects launching in the same year and no subsequent H2020 activity, it is unclear whether CHEMCONNECTION expanded or narrowed its research engagement after 2016-2020 — future collaborators should verify current activity directly.

How they like to work

CHEMCONNECTION has never led an H2020 project — they consistently join as a participant or third-party partner, which is typical for industry SMEs that contribute practical expertise without taking on coordination overhead. Their presence in MSCA-ITN training networks specifically suggests they are comfortable hosting early-stage researchers and offering industry exposure. With 25 unique partners across 8 countries from just 2 projects, they plugged into large, diverse consortia rather than tight bilateral arrangements.

Despite only two projects, CHEMCONNECTION reached 25 unique consortium partners across 8 countries — a high ratio that reflects the large, multi-node nature of MSCA training networks. Their network is genuinely European in scope, though the depth of individual relationships is unknown from available data.

What sets them apart

CHEMCONNECTION occupies a specific industrial niche — chiral chemistry and crystallization — that is critical to pharmaceutical manufacturing but rarely available in academic partners. For a consortium needing an industry host with hands-on process chemistry expertise in enantioselective synthesis, they offer credibility from an Oss-based pharmaceutical supply chain context. Their dual involvement in both molecular-scale nanomedicine and manufacturing-level chiral resolution makes them a versatile SME bridge between bench science and production reality.

Highlights from their portfolio

• CORE
  Directly matches CHEMCONNECTION's core industrial competency — continuous resolution and deracemization of chiral compounds by crystallization — making this the most diagnostic project for understanding what they actually do.
• NANOMED
  The only project for which EC funding was received (EUR 255,374), confirming their status as a paid industry partner hosting researchers within a Marie Curie training network.